La cadena de opciones muestra datos clave de las opciones de acciones de Regencell Bioscience a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Regencell Bioscience..

Regencell Bioscience (NASDAQ:RGC) Bolsa, Cadena de Opciones

Regal Entertainment Group Class A Common Stock

Regal Entertainment

Regal Entertainment Group

NYSE

Regencell Bioscience

Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGMH

ANTE

ARBE

ARLO

ATXI

Bakkt Holdings, Inc. Class A Common Stock

BKKT

FINV

GNPX

GRAB

HNRG

HROW

HYPR

KTCC

VRPX

VSTM

Las acciones de Harrow subieron un 23,1% en el premercado. Descubre qué otras compañías están ganando y perdiendo antes de la apertura.

Las acciones de Harrow (HROW) se disparan un 23%; aquí están 20 acciones que se mueven en el premercado

Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) reported quarterly losses of $(0.36) per share. This is a 14.29 percent increase over losses of $(0.42) per share from the same period last year.

Earnings

Regencell Bioscience H1 EPS $(0.36) Up From $(0.42) YoY

Shares of BlackBerry Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) rose sharply in today's pre-market trading following <a href="https://www.benzinga.com/markets/earnings/25/06/46084802/blackberry-stock-climbs-after-better-than-expected-q1-report-details">first-quarter results</a>.
BlackBerry reported quarterly earnings of two cents per share, which beat the analyst consensus estimate of zero cents. Quarterly revenue of $121.7 million beat the Street estimate of $112.18 million.
The company raised its fiscal 2026 revenue guidance from a range of $504 million to $534 million to a new range of between $508 million and $538 million, versus the $513.51 million estimate.
BlackBerry shares jumped 14.7% to $4.96 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>NaaS Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) surged 40.6% to $1.08 in pre-market trading after gaining 4% on Tuesday.</li>
<li>QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) gained 31.1% to $5.66 in pre-market trading after the company achieved a key 2025 milestone by successfully integrating its advanced Cobra separator process into baseline cell production.</li>
<li>Beeline Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNE#NASDAQ">BLNE</a>) gained 27.5% to $1.81 in pre-market trading after jumping 29% on Tuesday.</li>
<li>Liminatus Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) rose 22.5% to $32.70 in pre-market trading after jumping over 33% on Tuesday.</li>
<li>Genius Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>) jumped 20.8% to $0.8152 in pre-market trading after gaining more than 30% on Tuesday.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) climbed 14.6% to $26.30 in pre-market trading.</li>
<li>Impact BioMedical Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBO#NYSE">IBO</a>) gained 13.2% to $0.9566 in pre-market trading after dipping 48% on Tuesday. Impact BioMedical recently announced a limited merger and share exchange agreement with Dr Ashleys.</li>
<li>UP Fintech Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) rose 14.2% to $9.30 in pre-market trading.</li>
<li>Worthington Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) gained 10.5% to $66.44 in pre-market trading as the company reported better-than-expected fourth-quarter financial results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>XTI Aerospace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) shares tumbled 31.2% to $1.92 in pre-market trading after the company announced the pricing of $16 million public offering.</li>
<li>Torrid Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAAS#NASDAQ">MAAS</a>) shares fell 29.2% to $3.61 in pre-market trading.</li>
<li>FAST TRACK GROUP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRK#NASDAQ">FTRK</a>) dipped 19.2% to $2.01 in pre-market trading after dipping 60% on Tuesday.</li>
<li>OneMedNet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) declined 14.3% to $0.5850 in pre-market trading. OneMedNet shares jumped over 100% on Tuesday after the company entered into private placement agreements with accredited investors raising approximately $3.7 million in gross proceeds.</li>
<li>InspireMD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) dipped 12.1% to $2.19 in pre-market trading after the company received FDA premarket application approval for CGuard Prime Carotid Stent System.</li>
<li>Greenlane Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) fell 11.2% to $0.0079 in pre-market trading. Greenlane announced a 1-for-750 reverse stock split, effective on June 26.</li>
<li>XTL Biopharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTLB#NASDAQ">XTLB</a>) declined 11.1% to $1.16 in pre-market trading after gaining 28% on Tuesday.</li>
<li>Allot Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLT#NASDAQ">ALLT</a>) fell 9% to $8.75 in pre-market trading after the company announced the pricing of underwritten public offering of ordinary shares.</li>
<li>Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) fell 6.6% to $43.75 in pre-market trading after the company announced the pricing of upsized public offering of common stock.</li>
<li>FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) fell 5.4% to $216.85 in pre-market trading following soft first-quarter guidance.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46072226/top-3-real-estate-stocks-you-may-want-to-dump-in-june"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46072226/top-3-real-estate-stocks-you-may-want-to-dump-in-june">Top 3 Real Estate Stocks You May Want To Dump In June</a> </li>
</ul>
Photo via Shutterstock

ALLT

BLNE

CDTX

FTRK

GNLN

LIMN

Highest Performances Holdings Inc. - American Depository Shares

MAAS

NAAS

NSPR

ONMD

TIGR

XTIA

XTLB

Why BlackBerry Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 1% on Tuesday.
Shares of Kanzhun Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZ#NASDAQ">BZ</a>) fell sharply in today's pre-market trading after the company launched dual listing share offer of 30 million shares in Hong Kong and international markets to boost <a href="https://www.benzinga.com/quote/BZ">flexibility and investor base</a>.
Kanzhun shares dipped 2.7% to $17.20 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Upexi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) shares dipped 62.3% to $3.77 in pre-market trading after gaining 8% on Monday.</li>
<li>DeFi Development Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) fell 39.2% to $15.06 in pre-market trading. DeFi Development rescheduled release of shareholder letter and business update call to July.</li>
<li>CID HoldCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAIC#NASDAQ">DAIC</a>) dipped 12.8% to $31.80 in pre-market trading.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares declined 8.8% to $21.62 in pre-market trading after dipping 38% on Monday.</li>
<li>Sasol Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) dropped 8.2% to $4.69 in pre-market trading.</li>
<li>Ultrapar Participações S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UGP#NYSE">UGP</a>) fell 7.4% to $2.86 in pre-market trading.</li>
<li>SS Innovations International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) dipped 5.5% to $5.34 in pre-market trading.</li>
<li>Obsidian Energy Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OBE#NYSE">OBE</a>) fell 4.7% to $5.32 in pre-market trading.</li>
<li>Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) declined 3.3% to $50.22 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46067537/blackberry-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">BlackBerry Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo via Shutterstock

DAIC

DFDV

SSII

UPXI

Kanzhun, DeFi Development And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Shares of Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) rose sharply in today's pre-market trading after the company announced it will release top-line data from the 16-week induction period in the ongoing global Phase 2b REZOLVE-AD clinical trial of investigational <a href="https://www.benzinga.com/quote/NKTR">rezpegaldesleukin on June 24, 2025</a>.
Nektar Therapeutics shares jumped 30.3% to $12.44 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>iBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) surged 55.8% to $1.11 in pre-market trading after the company announced it will host a conference call to review its advances in obesity and cardiometabolic disease treatments and announce a third target in the AstralBio Collaboration in addition to Myostatin and Activin E.</li>
<li>Plus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) gained 27.7% to $0.2354 in pre-market trading after falling 5% on Monday.</li>
<li>Korea Electric Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEP#NYSE">KEP</a>) gained 20.1% to $12.44 in pre-market trading.</li>
<li>Liminatus Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) rose 18.5% to $23.74 in pre-market trading after jumping over 38% on Monday.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) jumped 17.2% to $0.3089 in pre-market trading after gaining 7% on Monday. Adial Pharmaceuticals recently announced the pricing of a $3.6 million offering.</li>
<li>Surf Air Mobility Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NASDAQ">SRFM</a>) climbed 16.2% to $2.23 in pre-market trading.</li>
<li>Rezolve AI PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) gained 11.8% to $2.28 in pre-market trading. Rezolve AI shares gained around 6% on Monday after the company announced it will join the Russell 2000 and Russell 3000 indexes</li>
<li>WF Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFF#NASDAQ">WFF</a>) rose 9.2% to $7.10 in pre-market trading after dipping 6% on Monday.</li>
<li>Teladoc Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) gained 5.8% to $8.36 in pre-market trading. Teladoc shares surged over 14% on Monday after Citron Research made comments about the company on social media.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Upexi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) shares tumbled 62.3% to $3.77 in pre-market trading after gaining 8% on Monday.</li>
<li>Maase Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAAS#NASDAQ">MAAS</a>) shares fell 52.4% to $4.73 in pre-market trading after jumping over 268% on Monday.</li>
<li>DeFi Development Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) dipped 39.2% to $15.06 in pre-market trading. DeFi Development rescheduled release of shareholder letter and business update call to July.</li>
<li>Robin Energy Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBNE#NASDAQ">RBNE</a>) declined 26.7% to $4.91 in pre-market trading after gaining 9% on Monday.</li>
<li>Indonesia Energy Corporation Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDO#NASDAQ">INDO</a>) dipped 25.4% to $3.64 in pre-market trading after falling around 4% on Monday.</li>
<li>TMD Energy Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMDE#NYSE">TMDE</a>) fell 23.8% to $1.76 in pre-market trading after jumping 30% on Monday.</li>
<li>Impact BioMedical Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBO#NYSE">IBO</a>) declined 22.1% to $1.16 in pre-market trading. Impact BioMedical shares jumped 345% on Monday after the company announced a limited merger and share exchange agreement with Dr Ashleys.</li>
<li>Nine Energy Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NINE#NYSE">NINE</a>) fell 21.7% to $0.9160 in pre-market trading after jumping around 14% on Monday.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) fell 8.8% to $21.62 in pre-market trading after dipping 38% on Monday.</li>
<li>Sasol Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) fell 8.2% to $4.69 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46067537/blackberry-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">BlackBerry Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo via Shutterstock

ADIL

IBIO

INDO

NINE

NKTR

PSTV

RBNE

RZLV

SRFM

TDOC

TMDE

Why Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock moved upwards by 339.0% to $1.59 during Monday's regular session. The company's market cap stands at $4.3 million. </li>
<li>Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) stock rose 100.14% to $42.07. The market value of their outstanding shares is at $272.6 million. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares moved upwards by 85.17% to $0.5. The company's market cap stands at $4.3 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock rose 42.23% to $20.52. The company's market cap stands at $375.3 million. </li>
<li>Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) stock increased by 31.24% to $2.83. The company's market cap stands at $66.9 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) shares increased by 31.08% to $0.32. The company's market cap stands at $30.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) shares decreased by 46.8% to $2.46 during Monday's regular session. The market value of their outstanding shares is at $433.1 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares decreased by 33.13% to $42.95. The market value of their outstanding shares is at $14.3 billion. </li>
<li>Quantum BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) shares decreased by 32.99% to $23.45. The company's market cap stands at $101.7 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) stock declined by 29.86% to $2.48. The company's market cap stands at $10.9 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares decreased by 29.68% to $26.73. The company's market cap stands at $494.6 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock fell 27.35% to $0.41. The company's market cap stands at $2.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CMPS

Hims & Hers Health, Inc. Class A Common Stock

HIMS

INDP

LUCY

QNTM

SKYE

WINT

12 Health Care Stocks Moving In Monday's Intraday Session

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.1% on Monday.
Shares of Vizsla Silver Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VZLA#NASDAQ">VZLA</a>) fell sharply in today's pre-market trading after the company reported a $100 million <a href="https://www.benzinga.com/quote/vzla">bought deal financing</a>.
Vizsla Silver shares dipped 7.2% to $3.05 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Next Technology Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) shares dipped 30.2% to $2.38 in pre-market trading after jumping over 158% on Friday.</li>
<li>COMPASS Pathways plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) fell 24.4% to $3.50 in pre-market trading. Compass Pathways said it successfully achieved primary endpoint in first Phase 3 trial evaluating COMP360 psilocybin for treatment-resistant depression.</li>
<li>SS Innovations International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) fell 20.7% to $5.49 in pre-market trading after gaining around 42% on Friday.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) declined 11.9% to $33.50 in pre-market trading after dipping 40% on Friday.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) fell 5.7% to $17.79 in pre-market trading.</li>
<li>Arqit Quantum Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQQ#NASDAQ">ARQQ</a>) fell 5.6% to $39.36 in pre-market trading after gaining 10% on Friday.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46023851/top-2-tech-stocks-that-could-sink-your-portfolio-in-june">Top 2 Tech Stocks That Could Sink Your Portfolio In June</a> </li>
</ul>
Photo via Shutterstock

ARQQ

Next Technology Holding Inc. - Ordinary Shares

NXTT

QUBT

VZLA

Vizsla Silver, COMPASS Pathways And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Shares of Sequans Communications S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) rose sharply in today's pre-market trading after the company announced a $384 million strategic investment to launch a <a href="https://www.benzinga.com/quote/SQNS">bitcoin treasury initiative</a>.
Sequans Communications shares jumped 42.2% to $2.72 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>OceanPal Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) surged 86.1% to $2.68 in pre-market trading after dipping around 35% on Friday.</li>
<li>Indaptus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares jumped 51.3% to $0.4086 in pre-market trading after tumbling 18% on Friday.</li>
<li>DIH Holding US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) gained 47.5% to $0.3260 in pre-market trading.</li>
<li>Houston American Energy Corp.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUSA#NYSE">HUSA</a>) gained 30.7% to $19.41 in pre-market trading after dipping 15% on Friday.</li>
<li>Robin Energy Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBNE#NASDAQ">RBNE</a>) rose 29.5% to $7.93 in pre-market trading. Robin Energy shares dipped 30% on Friday after the company announced the pricing of a $4.0M offering of 763,000 shares at $5.25 per share.</li>
<li>TMD Energy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDE#NASDAQ">TMDE</a>) jumped 28.2% to $2.57 in pre-market trading after falling more than 5% on Friday.</li>
<li>Exelixis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) fell 25.2% to $50.56 in pre-market trading after the company disclosed that Zanzalintinib combination with Atezolizumab achieved survival benefit in intent-to-treat population of metastatic colorectal cancer patients.</li>
<li>Zeta Global Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) climbed 17.6% to $16.67 in pre-market trading after gaining more than 12% on Friday.</li>
<li>W&amp;T Offshore, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTI#NYSE">WTI</a>) gained 9.1% to $2.36 in pre-market trading after falling 9% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>COMPASS Pathways plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) shares tumbled 30.8% to $3.20 in pre-market trading. Compass Pathways said it successfully achieved primary endpoint in first Phase 3 trial evaluating COMP360 psilocybin for treatment-resistant depression.</li>
<li>Next Technology Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) shares fell 30.2% to $2.38 in pre-market trading after jumping over 158% on Friday.</li>
<li>Shineco, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SISI#NASDAQ">SISI</a>) dipped 28.2% to $0.2293 in pre-market trading after falling around 6% on Friday.</li>
<li>SS Innovations International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) declined 20.7% to $5.49 in pre-market trading after gaining around 42% on Friday.</li>
<li>Dragonfly Energy Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) declined 17.3% to $0.2079 in pre-market trading after gaining 15% on Friday.</li>
<li>Moving iMage Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MITQ#NASDAQ">MITQ</a>) dipped 17% to $0.7055 in pre-market trading. Moving iMage Technologies shares jumped 54% on Friday after the company announced a $9 million contract with a national cinema exhibition customer regarding the sale and installation of 150 Barco laser projections along with a range of MIT-manufactured equipment..</li>
<li>Marin Software Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) fell 16.8% to $1.09 in pre-market trading after the company announced it received a delisting notice from the Nasdaq.</li>
<li>Citius Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) fell 16% to $2.21 in pre-market trading after jumping 70% on Friday.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) fell 15.4% to $0.27 in pre-market trading after gaining 32% on Friday.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) fell 11.9% to $33.50 in pre-market trading after dipping 40% on Friday.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46023851/top-2-tech-stocks-that-could-sink-your-portfolio-in-june">Top 2 Tech Stocks That Could Sink Your Portfolio In June</a> </li>
</ul>
Photo via Shutterstock

CTOR

DFLI

DHAI

EXEL

HUSA

MITQ

MRIN

PCSA

SISI

SQNS

ZETA

Why Sequans Communications Shares Are Trading Higher By Over 42%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) stock rose 84.4% to $4.21 during Friday's regular session. The market value of their outstanding shares is at $7.0 million. </li>
<li>SS Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) stock moved upwards by 43.27% to $6.99. The market value of their outstanding shares is at $944.7 million. </li>
<li>Anbio Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNNN#NASDAQ">NNNN</a>) shares rose 41.89% to $16.4. The market value of their outstanding shares is at $507.3 million. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares increased by 32.68% to $0.32. The company's market cap stands at $2.8 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock moved upwards by 29.67% to $2.01. The market value of their outstanding shares is at $110.9 million. </li>
<li>Quantum BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) shares increased by 23.92% to $37.4. The market value of their outstanding shares is at $87.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) shares fell 66.7% to $0.32 during Friday's regular session. The market value of their outstanding shares is at $10.3 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) shares declined by 48.89% to $0.3. The company's market cap stands at $8.2 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares declined by 43.12% to $36.03. The company's market cap stands at $824.3 million. </li>
<li>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock decreased by 22.74% to $9.22. The company's market cap stands at $545.7 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock declined by 21.64% to $4.02. The company's market cap stands at $3.4 million. </li>
<li>Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) shares fell 21.59% to $2.58. The market value of their outstanding shares is at $208.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APVO

CAPR

GALT

MBRX

NNNN

12 Health Care Stocks Moving In Friday's Intraday Session

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Friday.
The Dow traded up 0.34% to 42,314.63 while the NASDAQ rose 0.28% to 19,600.90. The S&amp;P 500 also rose, gaining, 0.29% to 5,998.05.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45993572/top-2-industrials-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Industrials Stocks That May Fall Off A Cliff In Q2</a>
Leading and Lagging Sectors Real estate shares jumped by 0.7% on Friday.
In trading on Friday, health care stocks fell by 0.3%.
Top Headline
Accenture Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) posted better-than-expected third-quarter earnings.
The company reported quarterly earnings of $3.49 per share, topping the analyst consensus estimate of $3.31. The company reported sales of $17.7 billion, slightly exceeding the analyst consensus estimate of $17.30 billion. Sales increased 8% in U.S. dollars and 7% in local currency.
Accenture narrowed its fiscal year 2025 revenue growth outlook to 6%-7% (prior 5%-7%) in local currency. The company forecasts 2025 diluted earnings of $12.77-$12.89 (prior $12.55-$12.79) per share compared to the consensus of $12.75.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Wheeler Real Estate Investment Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>) shares shot up 159% to $8.85. On May 21, Wheeler Real Estate Investment Trust announced it will implement a 1-for-7 reverse stock split.</li>
<li>Shares of Dragonfly Energy Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) got a boost, surging 74% to $0.3796 after gaining 6% on Wednesday.</li>
<li>Innovative Eyewear, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares were also up, gaining 73% to $3.9502 after the company announced a partnership with Smartech Retail Group to showcase the Reebok Powered by Lucyd collection and other brands at the new Smartech location in New York City.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Nature Wood Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWGL#NASDAQ">NWGL</a>) shares dropped 59% to $2.2950 after surging over 142% on Wednesday.</li>
<li>Shares of Moleculin Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) were down 48% to $0.3040 as the company announced a $5.9 million public offering.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) was down, falling 48% to $32.99 after dipping over 18% on Wednesday.</li>
</ul>
Commodities In commodity news, oil traded down 0.5% to $74.71 while gold traded down 0.6% at $3,389.00.
Silver traded down 2.5% to $36.005 on Friday, while copper fell 0.3% to $4.8400.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.4%, while Spain's IBEX 35 Index rose 1%. London's FTSE 100 rose 0.1%, Germany's DAX 40 surged 1.3% and France's CAC 40 rose 0.6% during the session.
Asia Pacific Markets
Asian markets closed mixed on Friday, with Japan's Nikkei falling 0.22%, Hong Kong's Hang Seng Index gaining 1.26%, China's Shanghai Composite falling 0.07% and India's BSE Sensex gaining 1.29%.
Economics
The Philadelphia Fed Manufacturing Index came in unchanged at -4.0 in June, versus market estimates of -1.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/46024423/how-to-earn-500-a-month-from-commercial-metals-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Commercial Metals Stock Ahead Of Q3 Earnings</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Intraday Update

NWGL

WHLR

Dow Surges Over 100 Points; Accenture Posts Upbeat Earnings

<h3>Gainers</h3>
<ul>
<li>Firefly Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>) stock rose 19.6% to $3.59 during Friday's pre-market session. The company's market cap stands at $38.5 million. </li>
<li>Quantum BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) stock moved upwards by 18.45% to $35.75. The market value of their outstanding shares is at $87.7 million. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares moved upwards by 17.97% to $0.29. The market value of their outstanding shares is at $2.8 million. </li>
<li>Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) stock moved upwards by 12.09% to $2.78. The market value of their outstanding shares is at $14.6 million. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) shares moved upwards by 11.87% to $35.73. The company's market cap stands at $419.7 million. </li>
<li>Galmed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) shares increased by 11.79% to $1.99. The market value of their outstanding shares is at $4.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares declined by 18.4% to $51.7 during Friday's pre-market session. The market value of their outstanding shares is at $824.3 million. </li>
<li>Terns Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>) shares decreased by 16.75% to $3.33. The market value of their outstanding shares is at $349.3 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares declined by 14.24% to $4.4. The company's market cap stands at $3.4 million. </li>
<li>Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) stock declined by 11.66% to $0.25. The market value of their outstanding shares is at $9.4 million. </li>
<li>Insight Molecular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMDX#NASDAQ">IMDX</a>) shares decreased by 11.4% to $2.8. The company's market cap stands at $90.3 million. </li>
<li>Opus Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRD#NASDAQ">IRD</a>) shares fell 10.75% to $0.83. The market value of their outstanding shares is at $55.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIFF

CODX

GLMD

IMDX

SMLR

TERN

VVOS

12 Health Care Stocks Moving In Friday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Friday.
Shares of Smith &amp; Wesson Brands Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>) fell sharply in pre-market trading after the company reported <a href="https://www.benzinga.com/markets/earnings/25/06/46007280/smith-wesson-q4-earnings-revenue-eps-fall-short-of-estimates-as-demand-slips-headwinds-will-likely-persist">worse-than-expected fourth-quarter EPS and sales.</a>
Smith &amp; Wesson Brands reported fourth-quarter revenue of $140.8 million, missing analyst estimates of $152.41 million, according to Benzinga Pro. The company reported adjusted earnings of 20 cents per share in the fourth quarter, missing estimates of 23 cents per share.
Smith &amp; Wesson Brands shares dipped 12.6% to $9.51 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Regencell Bioscience Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares fell 16.2% to $52.96 in pre-market trading after dipping over 18% on Wednesday.</li>
<li>QuantaSing Group Ltd- ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) fell 12.1% to $11.86 in pre-market trading.</li>
<li>Aptevo Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) fell 11.9% to $4.52 in pre-market trading. Aptevo Therapeutics shares jumped 82% on Wednesday after the company announced clinical data from its ongoing Phase 1b/2 RAINIER trial evaluating mipletamig.</li>
<li>Capricor Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) fell 7.4% to $11.04 in pre-market trading. Capricor Therapeutics recently announced Orphan Drug designation for Becker Muscular Dystrophy.</li>
<li>Mesoblast Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) fell 6.5% to $10.94 in pre-market trading.</li>
<li>Diginex Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) dropped 6.5% to $43.51 in pre-market trading.</li>
<li>Himalaya Shipping Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSHP#NASDAQ">HSHP</a>) declined 6.3% to $6.22 in pre-market trading.</li>
<li>AIRO Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRO#NASDAQ">AIRO</a>) fell 5.3% to $24.88 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45993572/top-2-industrials-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Industrials Stocks That May Fall Off A Cliff In Q2</a> </li>
</ul>
Photo via Shutterstock

AIRO

DGNX

HSHP

MESO

SWBI

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Shares of Cheetah Mobile Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMCM#NYSE">CMCM</a>) rose sharply in pre-market trading following <a href="https://www.benzinga.com/quote/cmcm/earnings">first-quarter results</a>.
Cheetah Mobile posted a quarterly loss of 11 cents per share, versus a year-ago loss of 32 cents per share. The company's quarterly sales rose to $35.69 million from $26.35 million in the year-ago period.
Cheetah Mobile shares surged 11.2% to $4.57 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Wheeler Real Estate Investment Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>) surged 129.6% to $7.85 in pre-market trading. On May 21, Wheeler Real Estate Investment Trust announced it will implement a 1-for-7 reverse stock split.</li>
<li>Dragonfly Energy Holdings Corp.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) shares jumped 108% to $0.4534 in pre-market trading after gaining 6% on Wednesday.</li>
<li>Baiya International Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIYA#NASDAQ">BIYA</a>) gained 36.2% to $1.13 in pre-market trading.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) jumped 32.2% to $0.32 in pre-market trading. On Tuesday, Processa Pharmaceuticals announced the pricing of $7 million public offering.</li>
<li>GMS Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) rose 21.2% to $98.22 in pre-market trading. GMS confirmed the receipt of $95.20 per share unsolicited buyout proposal from QXO.</li>
<li>Beasley Broadcast Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBGI#NASDAQ">BBGI</a>) rose 19.5% to $5.57 in pre-market trading after gaining 5% on Wednesday.</li>
<li>Arqit Quantum Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQQ#NASDAQ">ARQQ</a>) gained 15.2% to $43.74 in pre-market trading after surging over 22% on Wednesday.</li>
<li>Oscar Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) fell 13.3% to $21.31 in pre-market trading after gaining more than 16% on Wednesday.</li>
<li>GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) climbed 10.4% to $1.02 in pre-market trading. GeoVax Labs recently in a filing disclosed it will sell 6.15 million common units.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Nature Wood Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWGL#NASDAQ">NWGL</a>) shares tumbled 52.8% to $2.66 in pre-market trading after surging over 142% on Wednesday.</li>
<li>Regencell Bioscience Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares fell 16.2% to $52.96 in pre-market trading after dipping over 18% on Wednesday.</li>
<li>PTL Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLE#NASDAQ">PTLE</a>) dipped 16.2% to $0.30 in pre-market trading after surging 84% on Wednesday.</li>
<li>Cambium Networks Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) declined 12.9% to $0.36 in pre-market trading after gaining over 16% on Wednesday. Cambium Networks, last month, announced it received a Nasdaq noncompliance notice.</li>
<li>Smith &amp; Wesson Brands Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>) declined 12.6% to $9.51 in pre-market trading after the company reported worse-than-expected fourth-quarter EPS and sales.</li>
<li>Cellectar Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) dipped 12.4% to $0.32 in pre-market trading. Cellectar Biosciences announced a 1-for-30 reverse stock split, effective June 24.</li>
<li>QuantaSing Group Ltd- ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) fell 12.1% to $11.86 in pre-market trading.</li>
<li>Aptevo Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) fell 11.9% to $4.52 in pre-market trading. Aptevo Therapeutics shares jumped 82% on Wednesday after the company announced clinical data from its ongoing Phase 1b/2 RAINIER trial evaluating mipletamig.</li>
<li>Capricor Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) fell 7.4% to $11.04 in pre-market trading. Capricor Therapeutics recently announced Orphan Drug designation for Becker Muscular Dystrophy.</li>
<li>Mesoblast Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) fell 6.5% to $10.94 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45993572/top-2-industrials-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Industrials Stocks That May Fall Off A Cliff In Q2</a> </li>
</ul>
Photo via Shutterstock

BBGI

BIYA

CLRB

CMBM

CMCM

GOVX

OSCR

PTLE

Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket

U.S. stock futures were higher this morning, with the Dow futures gaining more than 50 points on Wednesday.
Shares of Aurora Cannabis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) fell 20.1% to $4.70 in pre-market trading following <a href="https://www.benzinga.com/quote/ACB/earnings">fourth-quarter results</a>.
Aurora Cannabis posted a quarterly loss of 24 cents per share.
Aurora Cannabis shares dipped 20.1% to $4.70 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares tumbled 22.4% to $15.35 in pre-market trading. CERo Therapeutics shares jumped 189% on Tuesday after the company received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for CER-1236.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) declined 14.1% to $66.98 in pre-market trading after gaining 30% on Tuesday.</li>
<li>Vince Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) dipped 13.4% to $1.28 in pre-market trading after dipping 12% on Tuesday. Vince Holding recently posted a first-quarter loss of 37 cents per share.</li>
<li>Jyong Biotech Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MENS#NASDAQ">MENS</a>) fell 9.5% to $9.15 in pre-market trading after jumping 35% on Tuesday. Jyong Biotech, recently, announced the pricing of $20 million initial public offering.</li>
<li>Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) fell 6.3% to $11.90 in pre-market trading after the company reported a $300 million proposed private placement of Convertible Senior Notes.</li>
<li>Fresenius Medical Care AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) declined 4.4% to $25.90 in pre-market trading after falling around 5% on Tuesday.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45970767/top-3-health-care-stocks-that-are-ticking-portfolio-bombs">Top 3 Health Care Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

BTDR

CERO

MENS

VNCE

Aurora Cannabis, Bitdeer Technologies Group And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Shares of Beyond Air, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) fell sharply in today's pre-market trading after the company posted <a href="https://www.benzinga.com/quote/xair/earnings">mixed fourth-quarter results.</a>
Beyond Air reported quarterly losses of nine cents per share, which beat the analyst consensus estimate of a loss of 12 cents. Quarterly revenue came in at $1.15 million, which missed the Street estimate of $1.39 million and is up from revenue of $470,000 from the same period last year
Beyond Air shares dipped 23.5% to $0.2179 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>PTL Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLE#NASDAQ">PTLE</a>) surged 148% to $0.4923 in pre-market trading after gaining 10% on Tuesday.</li>
<li>XCF Global, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAFX#NASDAQ">SAFX</a>) shares jumped 67.6% to $2.85 in pre-market trading after dipping 23% on Tuesday.</li>
<li>Leishen Energy Holding Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSE#NASDAQ">LSE</a>) jumped 53.5% to $8.52 in pre-market trading after tumbling 17% on Tuesday.</li>
<li>Gulf Resources, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GURE#NASDAQ">GURE</a>) gained 44.2% to $0.8652 in pre-market trading after gaining 5% on Tuesday.</li>
<li>Mesa Royalty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTR#NYSE">MTR</a>) rose 33.7% to $8.76 in pre-market trading after gaining 10% on Tuesday.</li>
<li>GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) rose 30% to $1.17 in pre-market trading. GeoVax Labs shares dipped 32% on Tuesday after the company in a filing disclosed it will sell 6.15 million common units.</li>
<li>Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) climbed 26.9% to $0.3921 in pre-market trading after dipping 18% on Tuesday.</li>
<li>TMC the metals company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) surged 11.8% to $6.07 in pre-market trading. Korea Zinc recently announced an equity investment of $85.2 million in the company.</li>
<li>Liminatus Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) gained 7.7% to $13.82 in pre-market trading after surging over 5% on Tuesday.</li>
<li>BiomX Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#NYSE">PHGE</a>) fell 7.7% to $0.4200 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Catalyst Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBIO#NASDAQ">CBIO</a>) shares tumbled 59.4% to $5.39 in pre-market trading. Crescent Biopharma recently completed closing of merger with GlycoMimetics and previously announced private placement of $200 million.</li>
<li>Biomea Fusion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) shares fell 26.2% to $2.14 in pre-market trading after the company announced the pricing of public offering of securities.</li>
<li>BP Prudhoe Bay Royalty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BPT#NYSE">BPT</a>) dipped 24.2% to $0.54 in pre-market trading. BP Prudhoe Bay Royalty Trust announced commencement of trust asset sale process.</li>
<li>Eyenovia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) declined 22.4% to $5.41 in pre-market trading. Eyenovia shares jumped 135% on Tuesday after the company announced it entered into a securities purchase agreement for a $50 million private placement in public equity with institutional accredited investors.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) dipped 22.4% to $15.35 in pre-market trading. CERo Therapeutics shares jumped 189% on Tuesday after the company received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for CER-1236.</li>
<li>Acurx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) declined 21% to $0.6485 in pre-market trading after the company announced exercise of warrants for $2.67 million gross proceeds.</li>
<li>LeddarTech Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) fell 14.4% to $0.1624 in pre-market trading. LeddarTech recently announced intention to file under the Bankruptcy and Insolvency Act in Canada.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) fell 14.1% to $66.98 in pre-market trading after gaining 30% on Tuesday.</li>
<li>Vince Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) fell 13.4% to $1.28 in pre-market trading after dipping 12% on Tuesday. Vince Holding recently posted a first-quarter loss of 37 cents per share.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45970767/top-3-health-care-stocks-that-are-ticking-portfolio-bombs">Top 3 Health Care Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

ACXP

BMEA

CBIO

EYEN

GURE

HSDT

LDTC

PHGE

SAFX

XAIR

Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket

Regencell Bioscience Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>), a Hong Kong-based biotech startup with no reported revenue, has gained more <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45960240/whats-going-on-with-regencell-bioscience-stock-today">than 59,000% in 2025</a>. 
The company, which claims to be developing traditional Chinese herbal treatments for childhood ADHD and autism, saw its market value reach nearly $30 billion, by Monday's close. 
Following a 38-for-1 stock split announced earlier in June, the stock skyrocketed by over 280% on Monday.
Read Next:<a href="https://www.benzinga.com/markets/tech/25/06/45971345/sunrun-first-solar-plunge-solar-stocks-hit-hard-by-trump-tax-bill-latest?utm_source=articleShare"> Sunrun, First Solar Plunge—Solar Stocks Hit Hard By Trump Tax Bill: Latest</a>&nbsp;
Regencell is now valued similarly to major companies like Lululemon Athletica, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>), and even surpasses the likes of Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)&nbsp; and Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>).
<h2 class="wp-block-heading">Revenue and Products</h2>
Despite its soaring stock, Regencell has not generated any revenue or received regulatory approval for its products. The company's main focus is a proprietary Traditional Chinese Medicine (TCM) formula. It&#8217;s developed in partnership with TCM practitioner Sik-Kee Au, who is also the father of the CEO Yat-Gai Au.&nbsp;
Regencell's latest<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001829667/000121390024090791/ea0218410-20f_regencell.htm"> annual report</a> shows net losses of $4.36 million and $6.06 million for the fiscal years ending June 2024 and 2023, respectively.
"We have not generated revenue from any TCM formulae candidates or applied for any regulatory approvals, nor have distribution capabilities or experience or any granted patents or pending patent applications and may never be profitable," read the filing.
Regencell's CEO owns a commanding 86% of the company's outstanding shares, as reported by FactSet, which could be contributing to a squeeze in the stock price.&nbsp;
<h2 class="wp-block-heading">Social Media Buzz&nbsp;</h2>
Regencell has recently been a top trending stock on Yahoo Finance and Stocktwits and social media commentary on Regencell stock has been mixed.&nbsp;
Some retail investors were enthusiastic about the stock's wild moves and others expressed skepticism. Some have compared its trading behavior to that of meme coins, noting the lack of news or clear business progress behind the dramatic price swings.
Benzinga reached out to Regencell for comment and has not heard back. 
Price Action: Regencell shares were up 23% at $73.80 Tuesday, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>.
Read Next:<a href="https://www.benzinga.com/news/retail-sales/25/06/45953480/alibaba-pdd-stocks-climb-chinas-retail-sector-gains-despite-us-tariffs?utm_source=articleShare">&nbsp;</a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/retail-sales/25/06/45953480/alibaba-pdd-stocks-climb-chinas-retail-sector-gains-despite-us-tariffs?utm_source=articleShare">Alibaba, PDD Stocks Climb As China&#8217;s Retail Sector Gains Despite US Tariffs</a></li>
</ul>
Image: Shutterstock

Stock Split

LULU

RDDT

SMCI

This Chinese Herb Stock Is Now Bigger Than Super Micro And Reddit

U.S. stocks were lower, with the Dow Jones index falling over 50 points on Tuesday.
Shares of Jabil Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) rose sharply during Tuesday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/JBL/earnings">third-quarter EPS and sales.</a>
The company reported quarterly adjusted earnings per share of $2.55, beating the analyst consensus estimate of $2.31. Quarterly sales of $7.83 billion outpaced the analyst consensus estimate of $7.06 billion.
Jabil shares climbed 12% to $202.75 on Tuesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Verve Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) shares jumped 75.4% to $11.00 after the company announced it will be acquired by Eli Lilly.</li>
<li>Digital Turbine Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) surged 44% to $6.92 after reporting better-than-expected fourth-quarter EPS and sales.</li>
<li>Regencell Bioscience Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) climbed 25% to $75.05.</li>
<li>Purecycle Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) surged 22.8% to $14.70 after the company announced it raised $300 million to support its global expansion toward 1B pounds. Also, the company announced a partnership with IRPC to build 130-million-pound polypropylene recycling facility in Thailand.</li>
<li>LiveWire Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVWR#NYSE">LVWR</a>) climbed 21.5% to $6.25.</li>
<li>Focus Impact BH3 Acquisition Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAFX#NASDAQ">SAFX</a>) gained 19.2% to $2.64.</li>
<li>PACS Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>) gained 17.1% to $11.89.</li>
<li>Fluence Energy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) rose 13.3% to $5.68.</li>
<li>John Wiley &amp; Sons Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLY#NYSE">WLY</a>) gained 12.8% to $41.79 after the company reported better-than-expected quarterly financial results and issued FY26 adjusted EPS guidance above estimates.</li>
<li>Intellia Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) gained 11.7% to $10.01.</li>
<li>Crispr Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) rose 7.6% to $44.72.</li>
<li>Oscar Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) gained 7.4% to $16.06.</li>
<li>Remitly Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELY#NASDAQ">RELY</a>) gained 7% to $20.90.</li>
<li>Reddit Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) rose 5.8% to $133.86.</li>
<li>Bath &amp; Body Works Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) gained 4.5% to $26.99.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45970767/top-3-health-care-stocks-that-are-ticking-portfolio-bombs">Top 3 Health Care Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

APPS

BBWI

CRSP

FLNC

LVWR

NTLA

PACS

RELY

VERV

Jabil Posts Upbeat Earnings, Joins Verve Therapeutics, John Wiley & Sons And Other Big Stocks Moving Higher On Tuesday

As of June 17, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Regencell Bioscience Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>)</h3>
<ul class="wp-block-list">
<li>Regencell Bioscience's 38-for-one forward stock split officially took effect on Monday. The split, announced at the beginning of June and distributed on June 13, gave shareholders 37 additional shares for each one they already owned. The stock began trading on a split-adjusted basis on Monday. The company stated that the goal of the split was to improve liquidity and make its shares more accessible to investors. The company's stock jumped around 548% over the past month and has a <a href="https://www.benzinga.com/quote/RGC">52-week high of $83.60</a>.</li>
<li>RSI Value: 94&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>RGC Price Action: Shares of Regencell Bioscience gained 276.2% to close at $60.00 on Monday.</li>
<li>Edge Stock Ratings: 91.92 Momentum score with Value at 93.51.</li>
</ul>
<h3 class="wp-block-heading">Verve Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>)</h3>
<ul class="wp-block-list">
<li>On May 14, Verve Therapeutics reported a year-over-year increase for first-quarter EPS results. &#8220;2025 is off to a strong start with both clinical and regulatory progress. Last month, we reported exciting initial data from the Heart-2 clinical trial, which demonstrated that a single infusion of VERVE-102, a base editing medicine targeting PCSK9, was well-tolerated and led to compelling, dose-dependent reductions in LDL-C. These data, along with ongoing durability data of up to two years from our Heart-1 clinical trial, suggest a product profile that could fundamentally transform the journey for patients living with cardiovascular disease from decades of chronic care to a one dose future,&#8221; said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve Therapeutics. The company's stock gained around 43% over the past month and<a href="https://www.benzinga.com/quote/VERV"> has a 52-week high</a> of $9.30.</li>
<li>RSI Value: 88.1</li>
<li>VERV Price Action: Shares of Verve Therapeutics rose 1.8% to close at $6.27 on Monday.</li>
</ul>
<h3 class="wp-block-heading">SAGE Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>)</h3>
<ul class="wp-block-list">
<li>On June 16, Supernus Pharmaceuticals agreed to acquire Sage Therapeutics for $12.00 per share in cash, or an aggregate of up to approximately $795 million. The deal consideration includes $8.50 per share in cash (or an aggregate of approximately $561 million) plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million). The company's stock gained around 32% over the past five days and has a <a href="https://www.benzinga.com/quote/SAGE">52-week high </a>of $13.46.</li>
<li>RSI Value: 86.2</li>
<li>SAGE Price Action: Shares of SAGE Therapeutics gained 35.4% to close at $9.07 on Monday.</li>
</ul>
Learn more about BZ Edge Rankings—click to see scores for other <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">stocks in the sector and see how they compare.</a>
Read This Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45948533/top-2-financial-stocks-that-may-plunge-in-q2"> Top 2 Financial Stocks That May Plunge in Q2</a></li>
</ul>

Short Ideas

SAGE

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

Shares of Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) rose sharply in today's pre-market trading after the company reported mixed results <a href="https://www.benzinga.com/quote/LEN/earnings">for the second quarter</a>.
Lennar reported quarterly earnings of $1.90 per share, which missed the Street estimate of $1.94. Quarterly revenue of $8.38 billion beat the analyst consensus estimate of $8.16 billion.
Lennar shares jumped 2.3% to $111.97 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>XCF Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAFX#NASDAQ">SAFX</a>) surged 113.1% to $4.71 in pre-market trading after dipping around 37% on Monday. XCF Global announced the appointment of new board of directors following business combination.</li>
<li>Salarius Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares jumped 110.9% to $1.33 in pre-market trading after the company disclosed it received an extension from the Nasdaq to regain compliance.</li>
<li>Verve Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) jumped 84.1% to $11.54 in pre-market trading.</li>
<li>Jianzhi Education Technology Group Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZ#NASDAQ">JZ</a>) gained 43% to $4.09 in pre-market trading after gaining 6% on Monday.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) rose 43.1% to $85.86 in pre-market trading. Regencell Bioscience shares jumped 276% on Monday after the company's 38-for-one forward stock split officially took effect.</li>
<li>Trident Digital Tech Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDTH#NASDAQ">TDTH</a>) rose 40.2% to $0.3428 in pre-market trading after gaining over 15% on Monday. Trident Digital Tech, last week, announced an initiative to raise up to $500 million to establish a corporate XRP treasury.</li>
<li>BGSF, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGSF#NYSE">BGSF</a>) climbed 39.9% to $5.65 in pre-market trading after the company agreed to sell Professional Division to INSPYR Solutions for $99 million in an all-cash deal.</li>
<li>Liminatus Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) surged 8.8% to $13.18 in pre-market trading after dipping 16% on Monday.</li>
<li>AIRO Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRO#NASDAQ">AIRO</a>) gained 8.7% to $33.69 in pre-market trading after surging 29% on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) shares tumbled 27.4% to $7.00 in pre-market trading. Jefferies, last week, downgraded the stock from Hold to Underperform and lowered its price target from $6 to $5.</li>
<li>LeddarTech Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) shares fell 24.9% to $0.1550 in pre-market trading after the company announced intention to file under the Bankruptcy and Insolvency Act in Canada.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) dipped 21.5% to $18.79 in pre-market trading. Barclays analyst Christine Cho, last week, maintained SolarEdge Technologies with an Underweight and raised the price target from $11 to $12.</li>
<li>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) declined 16.7% to $38.28 in pre-market trading.</li>
<li>CDT Environmental Technology Investment Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTG#NASDAQ">CDTG</a>) dipped 15.4% to $1.16 in pre-market trading.</li>
<li>Smart Powerr Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREG#NASDAQ">CREG</a>) declined 15% to $0.3060 in pre-market trading after dipping 38% on Monday.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) fell 11.4% to $0.2880 in pre-market trading after tumbling 7% on Monday. Adial Pharmaceuticals submitted the required briefing package to the FDA for the upcoming end of Phase 2 meeting.</li>
<li>Redwire Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) fell 10.1% to $18.48 in pre-market trading after the company announced a $200 million common stock offering.</li>
<li>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) declined 10.1% to $157.00 in pre-market trading. Jefferies analyst Julien Dumoulin-Smith, last week, upgraded First Solar from Hold to Buy and raised the price target from $157 to $192.</li>
<li>Array Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) fell 9.2% to $7.23 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45948410/5-stocks-in-the-spotlight-from-wall-streets-most-accurate-analysts-last-week-5">5 Stocks In The Spotlight From Wall Street&#8217;s Most Accurate Analysts Last Week</a> </li>
</ul>
Photo via Shutterstock

ARRY

BGSF

CDTG

CREG

ENPH

FSLR

SEDG

SLRX

TDTH

Why Lennar Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Regencell Bioscience Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares are soaring Monday after the company&#8217;s 38-for-one forward stock <a href="https://regencellbioscience.com/regencell-bioscience-holdings-limited-announces-forward-stock-split/">split officially took effect</a>.
What To Know: The split, announced at the beginning of June and distributed on June 13, gave shareholders 37 additional shares for each one they already owned. The stock began trading on a split-adjusted basis on Monday. The company stated that the goal of the split was to improve liquidity and make its shares more accessible to investors.
Regencell is an early-stage bioscience company based in Hong Kong. The company focuses on developing traditional Chinese medicine treatments for neurological disorders, specifically ADHD and autism spectrum disorder.
The stock split doesn't alter the company's fundamentals or financial outlook. The sharp spike in the company&#8217;s share price likely reflects speculative interest following the split. Investors may be reacting to the lower price per share post-split, which can drive short-term volume and volatility.
<h3 class="wp-block-heading">How To Buy RGC Stock</h3>
By now you're likely curious about how to participate in the market for Regencell Bioscience &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
RGC Price Action: Regencell Bioscience shares were up 276.5% at $59.21 at the time of publication Monday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45952716/stock-market-today-sp500-rises-iran-israel-nasdaq-near-record-highs">Wall Street Roars Back As Iran Signals De-Escalation: Nasdaq 100 Nears All-Time High </a></li>
</ul>
Image via Shutterstock.

What's Going On With Regencell Bioscience Stock Today?

WIIM

Regencell Bioscience shares are trading higher. The company effected a 38-for-1 forward stock split.

Regencell Bioscience Holdings Limited - Ordinary Shares

Comments

Regencell Bioscience

Regencell Bioscience (RGC) Opciones

Regencell Bioscience (NASDAQ:RGC) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL